Interferon-gamma gene signature (T-cell-inflamed signature)
An interferon-gamma signature is a readout of a handful of genes that T cells switch on when they are already inside a tumour and fighting; tumours with a high score respond to PD-1 drugs more often across many cancer types, but the score is not yet reliable enough to use outside trials.
Overview
What is measured: RNA expression of interferon-gamma-responsive and T-cell genes such as IFNG, CXCL9, CXCL10, CXCL11, IDO1, STAT1, HLA-DRA, PRF1, GZMB and CD8A. How: NanoString or RNA sequencing of tumour tissue; the 18-gene T-cell-inflamed gene expression profile of Ayers and colleagues (2017) was derived in pembrolizumab-treated patients and correlates with PD-L1 immunohistochemistry and tumour-infiltrating lymphocytes but adds to tumour mutational burden, the two being largely independent (Cristescu, Science 2018). A high score tracks higher response rates and longer progression-free survival to pembrolizumab across the KEYNOTE programme and to nivolumab with ipilimumab in melanoma; in the neoadjuvant NADINA trial almost every patient with a high score had a major pathological response and could skip adjuvant therapy. What a result changes: nothing in routine care yet; it stratifies trials, defines biomarker-guided arms (including follow-on trials that adapt adjuvant therapy to the score), and identifies cold tumours for combination strategies; it does not predict benefit from chemotherapy or anti-VEGF drugs. Where it matters: melanoma, advanced and stage III.
Similar pages
not linked directly; found by shared links- PairingNeoadjuvant immunotherapy → response-adapted adjuvant
Shares Major pathological response (MPR), Ipilimumab, Nivolumab, Melanoma.
- TermImmuno-oncology (IO) and checkpoint blockade
Shares PD-L1 expression testing (22C3, SP142, SP263), Tumour mutational burden (TMB), Ipilimumab, Nivolumab.
- TrialDifferent Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma
Shares Advanced melanoma (unresectable stage III and stage IV), Ipilimumab, Melanoma, Pembrolizumab.
- PersonAlexander Eggermont
Shares Stage III melanoma (after surgery), Ipilimumab, Melanoma, Pembrolizumab.
- PersonCaroline Robert
Shares Advanced melanoma (unresectable stage III and stage IV), Ipilimumab, Nivolumab, Melanoma.
- TrialSCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)
Shares Stage III melanoma (after surgery), Advanced melanoma (unresectable stage III and stage IV), Melanoma.
- PersonJeffrey S. Weber
Shares Stage III melanoma (after surgery), Ipilimumab, Nivolumab, Melanoma.
- IdeaTreat the draining lymph node before removing it
Shares Major pathological response (MPR), Ipilimumab, Nivolumab, Melanoma.